ADDEX THERAPEUTICS LTD
ADXNNASDAQTrading Snapshot
- Day Range
- $2.86 – $2.93
- 52-Week Range
- $3.10 – $11.97
- Volume
- $4.02B
- Avg Volume
- $4.49B
- Shares Outstanding
- 1.2M
- Next Earnings
- Nov 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $29,972
- Last Q Revenue
- $9,960
- P/E Ratio
- -0.4
- P/S Ratio
- 41.7x
- EPS (TTM)
- $-4.88
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +45.5%
Why Investors Own ADXN
- ✓High-growth profile — revenue up +13.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 56% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ADDEX THERAPEUTICS LTD
ADXN
StockOtter · stockotter.spaceAbout ADDEX THERAPEUTICS LTD
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
What Addex Therapeutics (ADXN) Said on Its Q2 Earnings Call
Addex Therapeutics (NASDAQ: ADXN) reported a CHF 1.1 million operating loss for the first half of 2026, compared with CHF 1.3 million a year earlier, as reduced outsourced research and development spending on its GABAB p
Addex Therapeutics Ltd (ADXN) Q2 2026 Earnings Call Transcript
Addex Therapeutics Ltd (ADXN) Q2 2026 Earnings Call Transcript
Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric
Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026
Geneva, Switzerland, September 24, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurolog
ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small mol